Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
601-620 of 653 trials

Head and Neck Cancer: Ficerafusp Alfa with Pembrolizumab

We are studying whether ficerafusp alfa combined with pembrolizumab can effectively treat patients with recurrent or metastatic head and neck cancer. This trial aims to find the best dose and compare its effects to a placebo.

Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma1-2 yearsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesCost ReimbursementOncology

High-Dose Influenza Vaccine for Adults 60 and Older

We are studying a new high-dose flu vaccine to see if it provides better immune protection than a standard vaccine for adults aged 60 and above. The trial will also assess the safety of this new vaccine.

Influenza Immunization1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementGastroenterologyInfectious Diseases

Vitamin D3 Supplementation: Young Adults vs. Seniors

We are comparing how vitamin D3 affects young adults and seniors to find the best supplementation approach for each group. The study also examines how respiratory illnesses might influence vitamin D levels.

Healthy Participants1-2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesAllergologyDermatologyEndocrinologyInfectious DiseasesInternal MedicineNephrologyOphthalmologyOtolaryngologyPediatricsPsychiatryPulmonology

Chronic Rhinosinusitis with Nasal Polyps: Tapering Biologics

We are studying whether patients with stable chronic rhinosinusitis can safely reduce their biologic medication dosage after a year. This trial compares the effects of Mepolizumab and Dupilumab on disease control.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesAllergologyOtolaryngology

Anal High-Grade Lesions: Sinecatechins Ointment

We are studying whether adding a topical ointment to standard treatment helps patients with high-grade anal lesions achieve better results. The goal is to see if it reduces lesions and prevents recurrence.

Anal High-Grade Squamous Intraepithelial Lesions (HSIL)1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteGastroenterologyOncology

ALS Treatment: EH-301 and N-Acetylcysteine with Riluzole

We are studying a new combination therapy for people with ALS to see if it can slow disease progression and improve muscle strength and quality of life. This trial compares the treatment to a placebo to evaluate its effectiveness.

Amyotrophic Lateral Sclerosis (ALS)1-2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Non-Small Cell Lung Cancer: QL2107 vs. Keytruda®

We are comparing a new treatment, QL2107, to Keytruda® for patients with resected non-small cell lung cancer. The study aims to see if QL2107 works similarly in the body and to evaluate its safety and immune response.

Non-small Cell Lung Cancer1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

THN391 for Early Alzheimer's Disease

We are testing a new medication to see if it is safe and well-tolerated in people with early Alzheimer's disease. This study will help us understand how the drug works in the body.

Alzheimer's Disease1-2 yearsSafety phase (I)Neurology

Plaque Psoriasis: Oral Piclidenoson Study

We are testing an oral medication called piclidenoson for people with moderate-to-severe plaque psoriasis. The goal is to see if it can significantly improve skin symptoms compared to a placebo.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Metastatic Colorectal Cancer: Fruquintinib and Tislelizumab Study

We are studying a new treatment combining Fruquintinib and Tislelizumab for patients with metastatic colorectal cancer without active liver metastases. The goal is to evaluate its effectiveness and safety while also assessing quality of life.

Metastatic Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Breast Cancer Treatment: Elacestrant Study

We are studying whether Elacestrant alone is as effective as Elacestrant with ovarian function suppression in premenopausal women with early-stage ER+/HER2- breast cancer. The trial also looks at the safety of these treatment options.

Breast Cancer1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Exenatide for Early Parkinson’s Disease Progression

We are studying whether Exenatide can slow down the progression of symptoms in people with early Parkinson’s disease. The trial will also assess the safety of this treatment over time.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteEndocrinologyNeurology

Bisphosphonate Treatment for Primary Hyperparathyroidism

We are studying whether bisphosphonate treatment before parathyroid surgery can improve bone, kidney, and heart health one year after the procedure. This trial compares the treatment to a placebo to see if there are any benefits.

Primary Hyperparathyroidism1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementEndocrinologyOrthopedics and Traumatology

Cancer Treatment: NTX-1088 and Pembrolizumab

We are studying the effects of NTX-1088 alone and with Pembrolizumab in patients with cancer. The goal is to see if this combination improves treatment outcomes.

Advanced Solid Tumors1-2 yearsSafety phase (I)Oncology

Daratumumab for Myalgic Encephalomyelitis (ME/CFS)

We are studying whether the drug daratumumab can help reduce symptoms in people with moderate to severe ME/CFS. The trial will also assess its safety compared to a placebo.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteInfectious DiseasesNeurology

Breast Cancer Treatment: Sac-TMT vs. Standard Chemotherapy

We are studying a new treatment for high-risk early-stage breast cancer to see if it works better than standard chemotherapy combined with pembrolizumab. This trial is for individuals with triple-negative or hormone receptor-low positive breast cancer.

Triple Negative Breast Cancer1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

WVE-007 for Adults with Overweight or Obesity

We are testing a new treatment called WVE-007 to see how it affects adults living with overweight or obesity. This study aims to understand its safety and how it may help with weight management.

Overweight and Obesity in Adults1-2 yearsSafety phase (I)EndocrinologyInternal Medicine

Ulcerative Colitis: Mirikizumab with Tirzepatide

We are studying whether combining mirikizumab with tirzepatide helps adults with moderately to severely active ulcerative colitis and obesity achieve better remission and weight loss than mirikizumab alone.

Obesity or OverweightUlcerative Colitis1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesPartially RemoteEndocrinologyGastroenterology

Crohn’s Disease: Mirikizumab with Tirzepatide

We are studying whether a combination of mirikizumab and tirzepatide helps adults with moderately to severely active Crohn’s disease achieve better remission and weight loss than mirikizumab alone.

Crohn’s DiseaseObesity or Overweight1-2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyGastroenterology

MK-7228: A New Medication Study

We are investigating the effects of MK-7228 in healthy men to understand its safety and how it works. This research may help inform future treatments.

Atherosclerosis1-2 yearsSafety phase (I)CardiologyInternal Medicine